TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02169947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss core
Description: The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss core plus maintenance
Description: The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
Study: NCT03170323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
Study: NCT01227824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir 400mg taken twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSK1349572 Placebo
Description: GSK1349572 placebo taken once daily
Study: NCT03170323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
Study: NCT02927119

Intervention type: DIETARY_SUPPLEMENT
Intervention: iodine
Description: ≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
Study: NCT01227824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: Abacavir/Lamivudine background therapy once daily
Study: NCT00779129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Lyposomal Doxorubicin
Description: Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study: NCT00507715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plantago ovata husk
Description: 5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
Study: NCT01227824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC
Description: Abacavir/Lamivudine background therapy once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: Tenofovir/emtricitabine background therapy once daily
Study: NCT00507715

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hemicellulose crystalline
Description: 5g effervescent powder t.id. during 14 days
Study: NCT03263091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT00088855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study: NCT02724436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Study: NCT01227824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC
Description: Tenofovir/emtricitabine background therapy once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir Placebo
Description: raltegravir placebo taken twice daily
Study: NCT01961583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclatide
Description: Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy
Study: NCT02812888

Intervention type: DRUG
Intervention: thionamide treatment for 3 months
Description: Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
Study: NCT00484185

Intervention type: DRUG
Intervention: BeneFIX (coagulation factor IX (recombinant))
Description: BeneFIX will be administered according to physician's discretion.
Study: NCT04052802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealing
Description: The materials will be applied to the demineralized fissures as stated in manufacturer's instructions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealing
Description: The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
Study: NCT01247298

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
Study: NCT04607798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency and pulsed electro-magnetic fields treatment
Description: Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
Study: NCT03203876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT02724436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radioembolization with Y-90
Description: radioembolization with Y-90
Study: NCT00243321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high dose-rate brachytherapy
Description: High dose-rate brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: intensity-modulated radiation therapy
Study: NCT02700256

Intervention type: BEHAVIORAL
Intervention: survey
Description: All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
Study: NCT02320396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine 5 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT03977207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium
Description: Thyroid hormone supplement
Study: NCT02688374

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment A: Nicorette 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicorette
Study: NCT03977207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral capsule
Study: NCT02508064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study: NCT01670201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Description: Silver dressing
Study: NCT02012010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual syringe infusion method
Description: Infuse the distension medium of hysteroscopy by manual syringe infusion method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pump infusion method
Description: Infuse the distension medium of hysteroscopy by pump infusion method
Study: NCT03001544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS23
Description: comparison of different doses
Study: NCT04209738

Intervention type: OTHER
Intervention: This is an observational study being conducted as a substudy of another trial.
Description: This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.

Intervention type: OTHER
Intervention: This is an observational study being conducted as a substudy of another trial.
Description: This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.

Intervention type: OTHER
Intervention: This is an observational study being conducted as a substudy of another trial.
Description: This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
Study: NCT00609921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ197
Description: treatment
Study: NCT02555800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT03021837

Intervention type: OTHER
Intervention: antenatal corticosteroid
Description: Will look at maternal glucose level after corticosteroids
Study: NCT02267928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Check Symptoms
Description: Symptoms are Checked

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Check Symptoms
Description: Symptoms are Checked

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncheck Symptoms
Description: Symptoms are Un-checked

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncheck Symptoms
Description: Symptoms are Un-checked

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experienced
Description: Focus of instructions is on symptoms the participant has experienced

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experienced
Description: Focus of instructions is on symptoms the participant has experienced

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Not Experienced
Description: Focus of instructions is on symptoms the participant has NOT experienced

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Not Experienced
Description: Focus of instructions is on symptoms the participant has NOT experienced
Study: NCT03427437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: caudal block was performed by ultrasound method
Study: NCT00932087

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for lipidomic study

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for lipidomic study

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for lipidomic study

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for lipidomic study
Study: NCT00824564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid plus standard of care
Description: Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
Study: NCT03312192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody Cage
Description: Anterior cervical discectomy and fusion with interbody cage placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody Cage and Anterior Plating
Description: Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
Study: NCT02588456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART22 cells
Description: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
Study: NCT03006783

Intervention type: PROCEDURE
Intervention: Cross-face nerve graft
Description: connecting the healthy facial nerve to the affected facial nerve
Study: NCT02262637

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: MicardisPlus®

Intervention type: DRUG
Intervention: MicardisPlus®

Intervention type: DRUG
Intervention: MicardisPlus®
Study: NCT04721353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin Hydrochloride
Description: prazosin hydrochloride oral 1-25 mg/day
Study: NCT02688374

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment A: Nicorette 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicorette

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment A: Nicorette 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicorette

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment A: Nicorette 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicorette

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment A: Nicorette 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicorette

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment A: Nicorette 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicorette
Study: NCT04926480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low and high flow Anesthesia
Description: comparison of hemodynamic changes in low and high flow anesthesia groups

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low and high flow Anesthesia
Description: comparison of hemodynamic changes in low and high flow anesthesia groups
Study: NCT02508064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study: NCT02114190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Mindful Eating Group
Description: Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
Study: NCT02114190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Integrated Group
Description: Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
Study: NCT02508064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study: NCT00743886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Description: injection onto injured area in ligament dose: 3-6mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: injection of 6 cc of saline into injured area
Study: NCT00418288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucagon-like-peptide-1
Description: intravenous infusion of 1.2pmol/kg/min for 7 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous infusion of 1.2pmol/kg/min
Study: NCT02783560

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Sleep Train Program
Description: This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Sleep Train Program
Description: This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Family Mealtimes Program
Description: This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
Study: NCT00119639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006, Nexavar)
Description: All subjects were given a open-label, single dose of 400mg sorafenib
Study: NCT01644214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 month follow up for pessary check in the clinic setting
Description: The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
Study: NCT02478333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176 (250 mg)
Description: Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176 (500 mg)
Description: Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176 (750 mg)
Description: Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo oral suspension once on Day 1 under fasted conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo oral suspension once on Day 1 under fasted conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
Study: NCT01878266

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Arm (1)
Description: A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
Study: NCT02783560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Family Mealtimes Program
Description: This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
Study: NCT03822884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa 40000 UNT/ML
Description: 40.000 UI subcutaneous single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa 40000 UNT/ML
Description: 40.000 UI subcutaneous single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa 40000 UNT/ML
Description: 40.000 UI subcutaneous single dose
Study: NCT01878266

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Arm (2)
Description: The total dose to 4500 cGy in 15 fractions in 3 weeks

Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional Arm (3)
Description: A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
Study: NCT03670485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study: NCT01214850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis vaccine
Study: NCT01705301

Intervention type: DEVICE
Intervention: WINCS
Description: The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
Study: NCT04012892

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD19 CART
Description: CD19 CART